Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Taiwan / NCT04926792
Enrolling by invitation Observational

Taiwan Registry for Leadless Pacemaker

NCT04926792 · tracked via the Priya Life Science Taiwan tracker
Sponsor
National Taiwan University Hospital
Phase
Observational
Started
2022-01-19
Last updated
2026-01-08

Condition(s) studied

Sick Sinus SyndromeAtrioventricular Block

Investigational drug(s) / intervention(s)

Leadless Pacemaker

Leadless Pacemaker: Leadless pacemaker implantation

Study summary

Taiwan Registry for Leadless Pacemaker is a nationwide registry for leadless pacemaker performance in Taiwan.

Eligibility

Sex
ALL
Min age
—
Max age
—
Healthy volunteers
No
Inclusion Criteria: 1. The patients who had successfully received leadless pacemaker implantation 2. The patients who attempt to receive leadless pacemaker implantation Exclusion Criteria: N/A

Primary outcome measure(s)

  • Acute complication — On the 1 day of implant procedure
    Any acute complication during procedure
  • Subacute complication — within 3 month after implant procedure
    Any subacute complication, including pacemaker syndrome
  • Leadless Pacemaker performance — aroung 12 months after implant proceure
    The AV synchrony or pacemaker parameters

Trial sites (1)

FacilityCityRegionStatus
National Taiwan University Hospital Taipei Taiwan

More National Taiwan University Hospital trials in Taiwan

Plasmapheresis in Amyotrophic Lateral Sclerosis With Autoantibody Against NRIP 2 (PALADIN2) Recruiting
Using Hydroxychloroquine (HCQ) to Treat Steatohepatitis Recruiting
Neoadjuvant Hormone and Radiation Therapy Followed by Radical Prostatectomy in Patients With High-Risk Prostate Cancer Recruiting
The Findings of Magnetic Resonance Imaging in Subtypes of Tics-related Disorders Recruiting
Comparisons of Treatment Responses of Early Syphilis to Benzathine Penicillin G With or Without Doxycycline Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT04926792 on ClinicalTrials.gov ↗ ← All trials in Taiwan